IGFBP3 and rosacea: While it does not replicate the full complexity of acne or rosacea, it allowed us to isolate and demonstrate CleodermTM’s ability to modulate central inflammatory pathways, such as the expression of LL-37 and IGFBP-3, which are relevant to these dermatoses.